Biodiversity Literature Repository

Submit to community
Liberated Data
Published April 4, 2024 | Version v1
Journal article Open

Impact of latent toxoplasmosis on pneumonic and non-pneumonic COVID-19 patients with estimation of relevant oxidative stress biomarkers

Authors/Creators

Description

Abdal-, Doaa A. Hamdy Ragaey A. Eid Heba Abdel-Tawab lah Wegdan M. Abd El Wahab Mohamed A. El-Badry Abdelrahman M. (2024): Impact of latent toxoplasmosis on pneumonic and non-pneumonic COVID-19 patients with estimation of relevant oxidative stress biomarkers. Folia Parasitologica (008) 71: 1-9, DOI: 10.14411/fp.2024.008, URL: https://doi.org/10.14411/fp.2024.008

Files

source.pdf

Files (509.8 kB)

Name Size Download all
md5:afc621c3ddbefd3496bfe2569e0209e0
509.8 kB Preview Download

Linked records

Additional details

Identifiers

LSID
urn:lsid:plazi.org:pub:FFC6FFC3FFBEFD34FFBFE2569E02FFE0

Related works

Cites
Publication: 10.1101/2020.03.30.20048165 (DOI)
Has part
Figure: 10.5281/zenodo.20663568 (DOI)
Figure: 10.5281/zenodo.20663570 (DOI)
Figure: 10.5281/zenodo.20663572 (DOI)

References

  • ABBASI M., DANESHPOUR M.S., HEDAYATI M., MOTTAGHI A., POURVALI K., AZIZI F. 2018: The relationship between MnSOD Val16Ala gene polymorphism and the level of serum total antioxidant capacity with the risk of chronic kidney disease in type 2 diabetic patients: a nested case-control study in the Tehran lipid glucose study. Nutr. Metab. (London). 15: 25.
  • ABDOLI A., FALAHI S., KENARKOOHI A. 2022: COVID-19-associated opportunistic infections: a snapshot on the current reports. Clin. Exp. Med. 22: 327-346.
  • ABED A.A., KALAF A.K. 2023: Serological detection for toxoplasmosis among patients with Covid-19 in Thi-Qar Province. Inst. Razi. Archives 78: 675-680.
  • AL-KHSHAB E.M. 2010: Some antioxidants level in seropositive toxoplasmosis woman in Mosul. Tikrit J. Pure Sci. 15: 17-22.
  • ALI M.S., SAHEB E.J. 2022: Serum levels of C-reactive protein and ferritin in COVID-19 patients infected with Toxoplasma gondii. Ann. Parasitol. 68: 47-54.
  • BAMOROVAT M., SHARIFI I., AFLATOONIAN M.R., KARAMOO- ZIAN A., TAHMOURESI A., JAFARZADEH A., HESHMATKHAH A., SHARIFI F., SALARKIA E., KHALEGHI T. 2022: Prophylactic effect of cutaneous leishmaniasis against COVID-19:a case-control field assessment. Int. J. Infect. Dis. 122: 155-161.
  • BARABOUTIS I.G., GARGALIANOS P., AGGELONIDOU E., AD- RAKTAS A. 2020: Initial real-life experience from a designated COVID-19 centre in Athens, Greece: a proposed therapeutic algorithm. SN. Compr. Clin. Med. 2: 689-693.
  • BINICI I., ALP H.H., HUYUT Z., GURBUZ E., GUNBATAR H., AK- MESE S., KARAHOCAGILM K., AKBAYH.I. 2023: The status of antioxidants and oxidative damage in patients with COVID-19. Ahi Evran. Med. J. 7: 114-123.
  • BRADBURY R.S., PIEDRAFITA D., GREENHILL A., MAHANTY S. 2020: Will helminth co-infection modulate COVID-19 severity in endemic regions? Nat. Rev. Immunol. 20: 342-342.
  • CAN H., ALAK S.E., KOSEOGLU A.E., DOSKAYA M., UN C. 2020: Do Toxoplasma gondii apicoplast proteins have antigenic potential? An in silico study. Comput. Biol. Chem. 84: 107158.
  • CHEN N., ZHOU M., DONG X., QU J., GONG F., HAN Y., QIU Y., WANG J., LIU Y., WEI Y. 2020: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395: 507-513.
  • CRISTIANA F., ELENA A., NINA Z. 2014: Superoxide dismutase: therapeutic targets in SOD related pathology. Health 6: 975-988.
  • DENKERS E.Y., KIM L., BUTCHER B.A. 2003: In the belly of the beast: subversion of macrophage proinflammatory signalling cascades during Toxoplasma gondii infection. Cell Microbiol. 5: 75-83.
  • EL-SAYED A., ALEYA L., KAMEL M. 2021: COVID-19: a new emerging respiratory disease from the neurological perspective. Environ. Sci. Pollut. Res. Int. 28: 40445-40459.
  • ELLMAN G.L. 1959: Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82: 70-77.
  • FEKADU A., SHIBRE T., CLEARE A.J. 2010: Toxoplasmosis as a cause for behaviour disorders-overview of evidence and mechanisms. Folia Parasitol. 57: 105.
  • FLEGR J. 2013: Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma -human model in studying the manipulation hypothesis. J. Exp. Biol. 216: 127-133.
  • FLEGR J. 2021: Toxoplasmosis is a risk factor for acquiring SARS- CoV-2 infection and a severe course of COVID-19 in the Czech and Slovak population: a preregistered exploratory internet cross-sectional study. Parasit. Vectors 14: 508.
  • GALVAN-RAMIREZ M.D.I. L., SALAS-LAIS A.G., MUNOZ-MEDI- NA J.E., FERNANDES-MATANO L., P EREZ L.R.R., FRANCO DE LEON K. 2023: Association of toxoplasmosis and COVID-19 in a Mexican population. Microorganisms 11: 1441.
  • GAO Y., LI T., HAN M., LI X., WU D., XU Y., ZHU Y., LIU Y., WANG X., WANG L. 2020: Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 92: 791-796.
  • GERAILI A., BADIRZADEH A., SADEGHI M., MOUSAVI S.M., MOUSAVI P., SHAHMORADI Z., HOSSEINI S.M., HEJAZI S.H., RAFIEI-SEFIDDASHTI R. 2023: Toxoplasmosis and symptoms severity in patients with COVID-19 in referral centers in Northern Iran. J. Parasit. Dis. 47: 185-191.
  • GHAFFARI S., KALANTARI N., GORGANI-FIROUZJAEE T., BAYANI M., JALALI F., DAROONKOLA M.A. 2021: Is COVID-19 associated with latent toxoplasmosis? Environ. Sci. Pollut. Res. Int. 28: 67886-67890.
  • GOLABI S., GHASEMI S., ADELIPOUR M., BAGHERI R., SUZUKI K., WONG A., SEYEDTABIB M., NAGHASHPOUR M. 2022: Oxidative stress and inflammatory status in COVID-19 outpatients: a health center-based analytical cross-sectional study. Antioxidants 11: 606.
  • HALLIWELL B. 2012: Free radicals and antioxidants: updating a personal view. Nutr. Rev. 70: 257-265.
  • HALONEN S., WEISS L. 2013: Toxoplasmosis. Handb. Clin. Neurol. 114: 125-145.
  • HEMPHILL A., MULLER N., MULLER J. 2019: Comparative pathobiology of the intestinal protozoan parasites Giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum. Pathogens 8: 116.
  • IESA M., OSMAN M., HASSAN M., DIRAR A., ABUZEID N., MAN- CUSO J., PANDEY R., MOHAMMED A., BORAD M., BABIKER H. 2020: SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New Microbes. New. Infect. 38: 100817.
  • JABLONSKA E., KIERSNOWSKA-ROGOWSKA B., RATAJCZAK W., ROGOWSKI F., SAWICKA-POWIERZA J. 2007: Reactive oxygen and nitrogen species in the course of B-CLL. Adv. Med. Sci. 52: 154-158.
  • JANKOWIAK L., ROZSA L., TRYJANOWSKI P., MOLLER A.P. 2020: A negative covariation between toxoplasmosis and COVID-19 with alternative interpretations. Sci. Rep. 10: 12512.
  • KHALEEL F.M., HAMEED A.S., DAWOOD A.S. 2020: Evaluation of antioxidant (GSH, Vitamin A, E, C) and MDA in Iraqi women with toxoplasmosis. Ind. J. Forensic. Med. Toxicol. 14: 1446- 1449.
  • KIRAN T., KARAMAN U., ARICI Y., YILDIZ S. 2019: Comparison of malondialdehyde, nitric oxide, adenosine deaminase and glutathione levels in patients with Entamoeba coli, Enterobius vermicularis, Giardia intestinalis, Demodex spp. positive, hydatid cyst and Toxoplasma gondii serum positive. Ann. Med. Res. 26: 1420.
  • LI Y., HU Y., YU J., MA T. 2020: Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia. Lab. Invest. 100: 794-800.
  • MARCHIORO A.A., COLLI C.M., DE SOUZA C.Z., DA SILVA S.S., TIYO B.T., EVANGELISTA F.F., HIGA L., CONCHON-COSTA I., FALAVIGNA-GUILHERME A.L. 2018: Analysis of cytokines IFN-γ, TNF-α, TGF-β and nitric oxide in amniotic fluid and serum of pregnant women with toxoplasmosis in southern Brazil. Cytokine 106: 35-39.
  • MARTINEZ CHAMORRO E., DIEZ TASCON A., IBANEZ SANZ L., OSSABA V ELEZ S., BORRUEL NACENTA S. 2021: Diagnostico radiologico del paciente con COVID-19. Radiologia 63: 56-73.
  • MEFTAHI G.H., JANGRAVI Z., SAHRAEI H., BAHARI Z. 2020: The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging". Inflamm. Res. 69: 825-839.
  • MEHRI F., RAHBAR A., GHANE E., SOURI B., ESFAHANI M. 2021: The comparison of oxidative markers between Covid-19 patients and healthy subjects. Arch. Med. Res. 52: 843-849.
  • MILLER C., SMITH N.C., JOHNSON A.M. 1999: Cytokines, nitric oxide, heat shock proteins and virulence in Toxoplasma. Parasitol. Today 15: 418-422.
  • MO P., XING Y., XIAO Y., DENG L., ZHAO Q., WANG H., XIONG Y., CHENG Z., GAO S., LIANG K. 2021: Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clin. Infect. Dis. 73: e4208-e4213.
  • MOHAMMED M.A., RAJAB K.I., AL-RAWI K.F., AL-DARWESH M.Y. 2020: Evaluation of some antioxidants and oxidative stress index in seropositive toxoplasmosis in pregnant women in Ramadi City of Iraq. Sys. Rev. Pharm. 11: 701-705.
  • MONTAZERI M., NAKHAEI M., FAKHAR M., PAZOKI H., PAGHEH A.S., NAZAR E., ZAKARIAEI Z., MIRZAEIAN H., SHARIFPOUR A., BANIMOSTAFAVI E.S. 2022: Exploring the association between latent Toxoplasma gondii infection and COVID-19 in hospitalized patients: first registry-based study. Acta. Parasitol. 67: 1172-1179.
  • MOOIWEER E., LUIJK B., BONTEN M.J., EKKELENKAMP M.B. 2011: C-Reactive protein levels but not CRP dynamics predict mortality in patients with pneumococcal pneumonia. J. Infect. 62: 314-316.
  • NICOLA M., ALSAFI Z., SOHRABI C., KERWAN A., AL-JABIR A., IOSIFIDIS C., AGHA M., AGHA R. 2020: The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int. J. Surg. 78: 185-193.
  • PARABONI M.L.R., MANFREDINI V., SCHREINER G.E., GONcALVES I.L., SILVEIRA C., COMMODARO A.G., BELFORT JR R. 2022: Comparative study of oxidative stress and antioxidative markers in patients infected with Toxoplasma gondii. Parasitol. Int. 91: 102645.
  • PARLOG A., SCHLUTER D., DUNAY I.R. 2015: Toxoplasma gondii induced neuronal alterations. Parasite. Immunol. 37: 159-170.
  • PAULES C.I., MARSTON H.D., FAUCI A.S. 2020: Coronavirus infections - more than just the common cold. JAMA 323: 707-708.
  • PEPYS M.B., HIRSCHFIELD G.M. 2003: C-reactive protein: a critical update. J. Clin. Invest. 111: 1805-1812.
  • PISOSCHI A.M., POP A. 2015: The role of antioxidants in the chemistry of oxidative stress: a review. Eur. J .Med. Chem. 97: 55-74.
  • ROE K. 2021: The symptoms and clinical manifestations observed in COVID-19 patients/long COVID-19 symptoms that parallel Toxoplasma gondii infections. J. Neuroimmune Pharmacol. 16: 513-516.
  • SALA G., MIYAKAWA T. 2020: Association of BCG vaccination policy with prevalence and mortality of COVID-19 (preprint). https://doi.org/10.1101/2020.03.30.20048165
  • SHARAF-EL-DEEN S.A. 2021: Toxoplasma gondii as a possible risk factor for COVID-19 severity: a case-control study. Egypt. J. Med. Microbiol. 30: 125-132.
  • SILVAGNO F., VERNONE A., PESCARMONA G.P. 2020: The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants 9: 624.
  • SINA S., MOHAMMAD J.M., REZA S., ANITA M., SOUDABEH E., HADI M. 2021: Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine. Eur. J. Med. Res. 26: 65.
  • SINHA P., MATTHAY M.A., CALFEE C.S. 2020: Is a "cytokine storm" relevant to COVID-19? JAMA Intern. Med. 180: 1152- 1154.
  • TAY M.Z., POH C.M., R ENIA L., MACARY P.A., NG L.F. 2020: The trinity of COVID-19: immunity, inflammation and interven- tion. Nat. Rev. Immunol. 20: 363-374.
  • TURKOGLU S.A., YAMAN K., ORALLAR H., CAMSARI C., KARABORK S., AYAZ E. 2018: Acute toxoplasmosis and antioxidant levels in the liver, kidney and brain of rats. Ann. Parasitol. 64: 241-247.
  • TONIN A., WEBER A., RIBEIRO A., CAMILLO G., VOGEL F., MOU- RA A., BOCHI G., MORESCO R., DA SILVA A. 2015: Serum levels of nitric oxide and protein oxidation in goats seropositive for Toxoplasma gondii and Neospora caninum. Comp. Immunol. Microbiol. Infect. Dis. 41: 55-58.
  • VELAVAN T.P., MEYER C.G. 2020: Mild versus severe COVID-19: laboratory markers. Int. J. Infect. Dis. 95: 304-307.
  • WEERATUNGA P., HERATH T.U., KIM T.-H., LEE H.-C., KIM J.- H., LEE B.-H., LEE E.-S., CHATHURANGA K., CHATHURANGA W.G., YANG C.-S. 2017: Dense Granule Protein-7 (GRA-7) of Toxoplasma gondii inhibits viral replication in vitro and in vivo. J. Microbiol. 55: 909-917.
  • WOLDAY D., TASEW G., AMOGNE W., URBAN B., SCHALLIG H.D., HARRIS V., RINKE DE WIT T.F. 2021: Interrogating the impact of intestinal parasite-microbiome on pathogenesis of COVID-19 in Sub-Saharan Africa. Front. Microbiol. 12: 614522.
  • WORLD HEALTH ORGANIZATION 2020: Clinical management of COVID-19: interim guidance, 27 May 2020.
  • WORLD HEALTH ORGANIZATION 2023: COVID-19 weekly epidemiological update, Edition 154, 3 August 2023.
  • WORWOOD M. 1990: Ferritin. Blood Rev. 4: 259-269.
  • YAGHOUBI N., YOUSSEFI M., JABBARI AZAD F., FARZAD F., YAVARI Z., ZAHEDI AVVAL F. 2022: Total antioxidant capacity as a marker of severity of COVID-19 infection: possible prognostic and therapeutic clinical application. J. Med. Virol. 94: 1558-1565.
  • YOUNG B., GLEESON M., CRIPPS A.W. 1991: C-reactive protein: a critical review. Pathology 23: 118-124.
  • ZUMLA A., HUI D.S., AZHAR E.I., MEMISH Z.A., MAEURER M. 2020: Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 395: e35-e36.